Opto Circuits India Limited (OCI), subsidiary Mediaid Inc has received the Brazilian FDA agency's Agencia Nacional de Vigilancia Sanitaria (ANVISA) approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the country and surrounding geographies.

The California-based international marketing arm will now be able to increase its presence in the Latin American region too.

According to Jayesh Patel, director, OCI, which is India's leading manufacturer of medical diagnostics and interventional products, "Brazil is the largest medical device market in Latin America and an access into the country's healthcare industry will help enhance peripheral geography sales too. Growth in Brazil's private health insurance and a hospital modernization drive by the government along with a strong consumer demand for latest technologies will drive further growth. Our SPO2 products are amongst the best in the world and we are confident of using the present opportunities to grow our market share in the geography."

Pulse oximetry which is used for the detection of arterial oxygen saturation and heart beat rate is one of the five 'vital signs' that are monitored on a patient. Continuous oxygenation monitoring in hospitals and other critical care settings is now a standard of care.

Mediaid products that will be sold in Brazil are: Model M30, M34, M900, M960 and variants thereof.

Opto Circuits (India) is a 100 percent EOU and a leading manufacturer of healthcare equipments in India. The product profile includes digital thermometers, sensors, probes, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. In 2001, OCI acquired 60 per cent stake in Advanced Micronic Devices (AMDL) to market and distribute its products in India. Mediaid came into existence with the acquisition of the patient monitoring division of Palco Labs, US, in end-2003. It also acquired EuroCor GmbH in 2006 which manufactures cardiac stents of various types, including drug eluting coronary stents used in critical cardiac care. In April 2007, OCI ventured into new product segments - urology, gastroenterology, gynaecology and orthopaedics after acquiring Devon Innovations Private Limited (Bangalore) and Ormed Medical Technology Limited (Chennai). In April 2008, it acquired US-based Criticare Systems, which designs, manufactures and markets patient monitoring systems, and gas benches for a wide range of hospitals.